The present study demonstrated that the pharmacological inhibition of TLR4 reduced skeletal muscle inflammatory and proteolytic pathway activation and reversed muscle wasting in LPS-treated cultured C2C12 myotubes and in mice with endotoxemia. The gene discussed is TLR4; the disease is serum lipopolysaccharide activity.